Urology
Volume 75, Issue 4 , Pages 773-778 , April 2010

Expression of the Sodium/Iodide Symporter in Human Prostate Adenocarcinoma

  • Michele Navarra

      Affiliations

    • Pharmaco-Biological Department, University of Messina, Messina, Italy
    • ,
  • Salvatore Micali

      Affiliations

    • Department of Urology, University of Modena, Modena, Italy
    • ,
  • Saverio M. Lepore

      Affiliations

    • Department of Pharmacobiological Sciences, University of Catanzaro “Magna Græcia,” Catanzaro, Italy
    • ,
  • Anna Maria Cesinaro

      Affiliations

    • Department of Pathology, University of Modena, Modena, Italy
    • ,
  • Marilena Celano

      Affiliations

    • Department of Pharmacobiological Sciences, University of Catanzaro “Magna Græcia,” Catanzaro, Italy
    • ,
  • Maria C. Sighinolfi

      Affiliations

    • Department of Urology, University of Modena, Modena, Italy
    • ,
  • Carmela De Gaetani

      Affiliations

    • Department of Pathology, University of Modena, Modena, Italy
    • ,
  • Sebastiano Filetti

      Affiliations

    • Department of Clinical Sciences, University of Roma “Sapienza,” Rome, Italy
    • ,
  • Giampaolo Bianchi

      Affiliations

    • Department of Urology, University of Modena, Modena, Italy
    • ,
  • Diego Russo

      Affiliations

    • Department of Pharmacobiological Sciences, University of Catanzaro “Magna Græcia,” Catanzaro, Italy
    • Corresponding Author InformationReprint requests: Diego Russo, M.D., Department of Pharmacobiological Sciences, University of Catanzaro “Magna Graecia,” Viale Europa, Germaneto, 88100 Catanzaro, Italy

Received 6 March 2009 ,Accepted 3 October 2009.

References 

  1. Yin M, Bastaky S, Chandran U, et al. Prevalence of incidental prostate cancer in general population: a study of healthy organ donors. J Urol. 2008;179:892–895
  2. Heidenreich A, Bolla M, Joniau S, et al. Guidelines on Prostate Cancer, EAU Guidelines 2009 Edition. http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/Prostate_Cancer.pdfAccessed October 1, 2009
  3. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery what we have learned and where we are going. J Urol. 1999;162:293–306
  4. Stamey TA, Caldwell M, McNeal JE, et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol. 2004;172(4 Pt 1):1297–1301
  5. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature. 1996;379:458–460
  6. Dohan O, De la Vieja A, Paroder V, et al. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev. 2003;24:48–77
  7. Spitzweg C, Joba W, Eisenmenger W, et al. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab. 1998;83:1746–1751
  8. Lacroix L, Mian C, Caillou B, et al. Na(+)/I(−) symporter and Pendred syndrome gene and protein expressions in human extra-thyroidal tissues. Eur J Endocrinol. 2001;144:297–302
  9. Wapnir IL, Van de Rijn M, Nowels K, et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab. 2003;88:1880–1888
  10. Arturi F, Russo D, Schlumberger M, et al. Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab. 1998;83:2493–2496
  11. Scipioni A, Ferretti E, Soda G, et al. hNIS protein in thyroid: the iodine supply influences its expression and localization. Thyroid. 2007;17:613–618
  12. Castro MR, Bergert ER, Beito TG, et al. Development of monoclonal antibodies against the human sodium iodide symporter: immunohistochemical characterization of this protein in thyroid cells. J Clin Endocrinol Metab. 1999;84:2957–2962
  13. Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early stage prostate cancer: review of the literature. Cancer. 2008;112:1650–1659
  14. Zippe CD, Kedia AW. Locally invasive prostate cancer: an evolving concept of advanced disease. In:  Klein EA editors. Management of Prostate Cancer. Totowa, NJ: Humana press; 2000;p. 223–243
  15. Riesco-Eizaguirre G, Santisteban P. A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol. 2006;155:495–512
  16. Spitzweg C, Zhang S, Bergert ER, et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res. 1999;59:2136–2141
  17. Spitzweg C, O'Connor MK, Bergert ER, et al. Treatment of prostate cancer by radioiodide therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res. 2000;60:6526–6530
  18. Spitzweg C, Dietz AB, O'Connor MK, et al. In vivo sodium iodide symporter gene therapy of in prostate cancer. Gene Ther. 2001;8:1524–1531
  19. Kakinuma H, Bergert ER, Spitzweg C, et al. Probasin promoter (ARR2PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res. 2003;63:7840–7844
  20. Foley R, Lawyer M, Hollywood D. Gene-based therapy in prostate cancer. Lancet Oncol. 2004;5:469–479
  21. Haberkorn U, Kinscherf R, Kissel M, et al. Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. Gene Ther. 2003;10:774–780
  22. Huang D, Casale GP, Tian J, et al. Quantitative fluorescence imaging analysis for cancer biomarker discover application to beta-catenin in archived prostate specimens. Cancer Epidemiol Biomarkers Prev. 2007;16:1371–1381
  23. Trouttet-Masson S, Selmi-Ruby S, Bernier-Valentin F, et al. Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors. Am J Pathol. 2004;165:25–34
  24. Sodrè AK, Rubio IG, Galrão AL, et al. Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increate intracellular protein staining. J Clin Endocrinol Metab. 2008;93:4141–4145
  25. Kogai T, Taki K, Brent GA. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer. 2006;13:797–826
  26. Schlumberger M, Lacroix L, Russo D, et al. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab. 2007;3:263–269
  27. Barton KN, Stricker H, Brown SL, et al. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther. 2008;16:1761–1769
  28. Hyer S, Vini L, O'Connell M, et al. Testicular dose and fertility in men following I131 therapy for thyroid cancer. Clin Endocrinol. 2002;56:755–758
  29. Ceccarelli C, Canale D, Battisti P, et al. Testicular function after I131 therapy for hyperthyroidism. Clin Endocrinol. 2006;65:446–452
  30. Sawka AM, Lea J, Alshehri B, et al. A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin Endocrinol. 2008;68:610–617

 This study was supported by grants from the “Fondazione Umberto Di Mario” (to D.R. and S.F.).

 S. M. Lepore is fellow of Ph.D. Program in Pharmaceutical Sciences at University of Catanzaro.

 Michele Navarra and Salvatore Micali contributed equally to this work.

PII: S0090-4295(09)02722-8

doi: 10.1016/j.urology.2009.10.011

Urology
Volume 75, Issue 4 , Pages 773-778 , April 2010

Article Tools

* Image Usage & Resolution